We have conducted a phase II outpatient trial testing weekly oral administration of idarubicin (ZAVEDOS-ZVD) alone to determine the rate of objective response and toxicity in poor risk acute myeloid leukemia (AML) patients over 60 years of age. The treatment consisted of three phases: induction, with 20 mg/m 2 of ZVD on days 1, 8, 15 and 22; consolidation with 20 mg/m 2 of ZVD for 4 weeks; and maintenance with six cycles lasting 3 months and consisting of oral 6 mercapto-purine 2 mg/kg/day, 4 days a week for 2 months; subcutaneous cytarabine 1 mg/kg, once a week for 2 months; and oral ZVD 20 mg/m 2 on day 1 and day 8 of the third month. In case of failure after induction course, patients received salvage treatment with 4 weekly oral doses of 40 mg/m 2 ZVD. Fifty-one patients with a median age of 76 years were enrolled and could receive induction course. Of these 51 patients, 37 could receive subsequent courses, which consisted either of consolidation, or salvage. Only 11 patients underwent maintenance treatment. Sixty-three percent of patients had to be hospitalized during induction, for a median duration of 14.5 days, and 87% required hospitalization during salvage for a median duration of 17.5 days. Only five patients (38%) required hospitalization during consolidation. There were three toxic deaths (6%), two from hemorrhage and one from pulmonary embolism. The overall response rate was 29%, with 12 patients in complete response (25%) and two in partial response (4%). The median overall survival rate is 4 months for the whole population, and the median DFS is 9.6 months among the 14 responding patients. The results of this trial show that this new weekly schedule of oral ZVD chemotherapy is feasible and effective in poor risk elderly patients with AML. This regimen may be helpful for patients unable to tolerate intensive intravenous regimens, and is a real alternative to palliative treatments.
Introduction
Acute myeloid leukemia (AML) is a disease of the elderly, with a median age at onset of between 60 and 65 years. 1 The treatment of AML in elderly patients is controversial. Only palliative treatment can be offered in some cases, in which survival rarely exceeds 6 months. Low-dose (LD) cytarabine (Ara-C) has been widely tested in AML, given its effect on cell differentiation. This approach is considered less toxic than intensive treatment. Most reported studies give complete response (CR) rates ranging between 20 and 40%. 2 Most responses were short, and median survival remained between 8 and 12 months. Anthracyclines are a standard component of combination chemotherapy regimen for AML. Daunorubicin (DNR) gives a CR rate of 50% to 55% when used alone, 3 and 55% to 72% when used in combination with Ara-C. 4, 5 Recent improvements in supportive care have allowed the delivery of intensive chemotherapy to AML patients over 60 years of age. However, such combination chemotherapy regimens are poorly tolerated by most elderly patients, and the toxic death rate remains high, owing mainly to infections favored by the resulting myelosuppression. 6, 7 The addition of hematopoietic growth factors (G-CSF, GM-CSF) to those regimens gives only a marginal effect on CR rate, while mortality is not decreased. 8 Thus, if some elderly patients may tolerate intensive treatment, others are in poor general condition or have concomittant conditions contraindicating intensive intravenous chemotherapy. Such patients only qualify for palliative treatment or chemotherapy with LD subcutaneous cytarabine. These patients clearly need new cytotoxic drugs that are both effective and well tolerated, in order to improve the quality of survival. The new oral anthracycline idarubicin (ZAVEDOS-ZVD) provides such an alternative. Oral ZVD is highly lipophilic and rapidly absorbed. 9 Oral ZVD monotherapy proved effective in elderly AML patients at doses ranging from 20 to 30 mg/m 2 /day on 3 consecutive days. The CR rates ranged between 22% and 40% according to the dose. [10] [11] [12] Oral ZVD has also been used in combination with other drugs, such as LD Ara-C and etoposide, giving CR rates between 40% and 60%. [13] [14] [15] However, those schedules of oral ZVD are both associated with hematological and extrahematological toxicity that hinders their use in poor risk elderly patients with AML.
Weekly oral administration of ZVD seems feasible, given the pharmacokinetic properties of ZVD and its active metabolite, idarubicinol. 9 Indeed, the median half-life of idarubicinol is about 46 h, and can reach 70 h. Furthermore, idarubicinol accumulates in plasma. Weekly dosing has already been used to treat solid tumors (breast and prostate cancer), with moderate hematological and extrahematological toxicity. 16, 17 We tested weekly oral administration of ZVD to determine the rate of objective responses and toxicity in a phase II outpatient trial involving poor risk AML patients over 60 years of age. We report the results in 51 elderly patients with de novo AML or in first relapse, who were not eligible for intensive intravenous treatment.
Patients and methods

Patient selection
Eligibility criteria were: (1) morphologically documented AML according to the FAB classification (except M3 AML); (2) newly diagnosed or first relapse AML (if the interval between first-line treatment and relapse exceeded 12 months); (3) age above 60 years; (4) life expectancy exceeding 3 months; (5) at least one contraindication to conventional intensive intravenous chemotherapy, ie poor physical con-dition (WHO performance status у2), or risks associated with bone marrow aplasia outweighing the potential benefits; (6) patients who refused intensive treatment. Ineligibility criteria were: (1) white blood cell count above 50 × 10 9 /l (those situations are often characterized by a high mitotic rate and rapid proliferation); (2) AML secondary to a documented history of myelodysplasia or AML secondary to chemotherapy or radiotherapy; (3) central nervous system involvement; (4) cardiac disorders (ejection fraction Ͻ55%), uncontrolled infections, hepatic or renal dysfunction, or chronic respiratory insufficiency. Written informed consent was obtained from all patients prior to enrollment.
Treatment schedule
This was an open-label multicenter single-agent trial in elderly patients with de novo AML or in first relapse. It consisted of three phases.
Induction therapy:
All patients received oral ZVD alone at a dose of 20 mg/m 2 /week for 4 weeks, on days 1, 8, 15 and 22. Response to this induction therapy was evaluated 28 days after starting treatment, on the basis of both the blood cell count and bone marrow cellularity.
Consolidation therapy:
This sequence also consisted of oral ZVD (Pharmacia & Upjohn, Nerviano, Italy) alone at a dose of 20 mg/m 2 /week for 4 weeks. The start date of consolidation therapy depended on disease status on day 28, beginning on day 28 if the patient was in partial response (PR), and day 45 if a CR was obtained. In case of failure on day 28, patients received salvage treatment. In case of persistent cytopenia and a cell-poor bone marrow aspirate on day 28 with less than 5% of blast cells, a new marrow aspirate was obtained on day 45. Patients in CR or PR entered the consolidation phase, while patients in failure received salvage treatment.
Salvage therapy:
This was delivered in case of failure and comprised 4 weekly oral doses of 40 mg/m 2 ZVD. Salvage therapy rapidly followed the induction course in case of failure on day 28, and was started later if failure was documented on day 45.
Maintenance therapy:
A bone marrow aspirate was obtained on day 75 to assess the remission status in patients who initially responded. Maintenance therapy was scheduled for patients still in CR or PR, and included six cycles of 3 months duration consisting of oral 6 mercapto-purine (6 MP) 2 mg/kg/day, 4 days a week for 2 months; subcutaneous Ara-C 1 mg/kg, once a week for 2 months; and oral ZVD 20 mg/m 2 on day 1 and day 8 of the third month. For refractory and relapsed patients on day 75, the treatment was chosen by the patients' physicians.
This regimen was designed to be ambulatory, but patients were hospitalized if they developed serious disease-related symptoms. Physical examination was performed weekly. Blood cell counts and blood chemistry analyses were done twice a week during induction, consolidation, and salvage, then once a week during maintenance. Cardiac evaluation (ultrasonography or MUGA scan) was performed after induction, consolidation, and salvage, and was repeated every 6 months during maintenance.
Concomitant medications:
For the prophylaxis of metabolic and renal complications, we used oral hydration (3.5 l of oral fluids), intravenous urate-oxydase on day 1, and oral allopurinol for 7 days at a dose of 300 mg/day. Oral antibiotics were given if patients developed fever (у38°C); patients were hospitalized for intravenous antibiotic therapy if no improvement was obtained after 2 days. Hematopoietic growth factors were not allowed.
Blood product support:
Red blood cells (RBC) transfusions were to be made for hemoglobin level Ͻ90 g/l, with regard to the clinical features of our population which was aged. For platelet transfusion, our practice was similar to that reported and recommended in the literature. Patients received platelet transfusion when platelet count was Ͻ20 × 10 9 /l or when patients experienced bleeding symptoms.
Definition of responses
Responses were evaluated by Cancer and Leukemia Group B criteria. 18 CR was defined as a normal blood cell count (neutrophils у1.0 × 10 9 /l, platelets у100 × 10 9 /l, and no RBC transfusion requirement), and a normal bone marrow cellularity with less than 5% blast cells. PR was defined as a normal blood cell count with a marrow blast cell percentage ranging between 5 and 30%. Failure was defined when these conditions were not met. Hematologic and extrahematologic toxicity was assessed according to NCI-CTC criteria.
Pharmacokinetic study
A pharmacokinetic study was performed in 17 patients to assess residual plasma levels of idarubicin and idarubicinol on days 8, 15, 22 and 29. These patients had to receive at least one full induction course.
Statistical methods
Patients' characteristics are reported as medians and ranges. Chi-square tests were applied to categorical data when analyzing the distribution of the population in different subgroups. All patients were included in the safety analysis, median and range were assessed. All patients were included in the survival analysis. Survival curves were estimated by the Kaplan-Meier method. Overall survival (OS) was calculated from the inclusion date. Disease-free survival (DFS) was calculated among responding patients from inclusion date to the date of first relapse.
Results
Patients' characteristics
From September 1996 to July 1997, 51 patients were registered from 20 centers. Three patients were secondary with- drawn from the study with regard to failing eligibility criteria: one patient with hepatic impairment, one patient with renal dysfunction, and one patient who was in first relapse with an interval between first-line treatment and relapse Ͻ12 months. Clinical characteristics of the 51 patients are listed in Table  1 . There were 28 men and 23 women. Median age was 76 years (range 61-89), with 88% of patients more than 70 years, and 57% above 75 years. Six patients less than 70 years were enrolled in the study and did not receive intensive chemotherapy because of poor performance status (у2) for four patients, first relapse for one patient, and refusal of intensive treatment for one patient. Eight patients presented with extramedullary involvement at diagnosis: four had an enlarged spleen, three a skin involvement, and one had enlarged cervical lymph nodes. Table 2 shows hematological features of the 
Delivery of chemotherapy
All 51 patients received at least one course of induction chemotherapy. The mean relative dose-intensity (RDI) for the induction course was 92%. Fourteen patients did not receive further treatment because of death (n = 8), poor performance status (n = 2), or patient's or physician's refusal (n = 4). Only 37 patients could receive subsequent courses, which consisted either of consolidation (n = 7) or salvage (n = 30, of whom six received subsequent consolidation). In these two phases of treatment the mean RDI delivered were 97% and 74%, respectively. Only 11 of the 51 patients underwent maintenance treatment, either after induction plus consolidation (n = 5) or after induction plus salvage (n = 6).
Hematological toxicity (Table 3) Induction therapy: Sixty-three percent of patients had to be hospitalized during this phase, for a median of 14.5 days (range 2-49). Median duration of grade 4 neutropenia (84% of patients) and grade 4 thrombocytopenia (49% of patients) was 28 days (range 3-79) and 15 days (range 2-58), respectively. During induction therapy, 80% and 59% of the patients Table 3 Hematological toxicity received RBC and platelet transfusions, respectively. The median number of both types of blood product was two per patient (ranges 1-6 and 1-10, respectively). Three patients experienced severe bleeding; two died of cerebral hemorrhage and one recovered after a subdural hemorrhage.
Consolidation therapy:
Of 13 patients who received consolidation, five patients (38%) required hospitalization, for a median of 8 days (range 2-28). Only one patient had grade 4 thrombocytopenia (47 days), and three patients had grade 4 neutropenia for a median duration of 47 days (range 16-64). Fifty-four percent and 15% of the patients received RBC and platelets, respectively.
Salvage therapy:
Of the 30 patients who received salvage treatment, 87% required hospitalization for a median duration of 17.5 days (range 2-38). The median duration of grade 4 neutropenia was 27.5 days (range 1-54), and that of grade 4 thrombocytopenia 16 days (range 1-42). Ninety percent and 83% of the patients required at least one transfusion of red cells and platelets, respectively.
Extrahematological toxicity (Table 4)
Gastrointestinal toxicity was mild, with diarrhea, nausea, vomiting, or mucositis рgrade 2. Only 10% and 23% of patients experienced a уgrade 3 gastrointestinal toxicity during induction and salvage courses, respectively. No cardiac toxicity was seen, but one patient had a subclinical reduction in the left ventricular ejection fraction (LVEF). Four patients (8%) during induction, and 20% during salvage therapy required parenteral antibiotics for уgrade 3 documented infections. Unexpected serious adverse events comprised one case of general erythema which resolved spontaneously, two cases of pulmonary embolism, one of which was fatal, one bladder retention which resolved, one acute respiratory failure which was fatal, and one suicide which was fatal.
Response and survival (Table 5)
Among the 48 eligible patients, the overall response rate was 29%, with 12 patients in CR (25%) and two in PR (4%). Seven of the 12 CRs were achieved after salvage therapy. No response could be obtained in 15 patients, with a failure rate at 3%. Nineteen patients died within 3 months, with two early deaths (before day 8), six deaths during induction, and 11 deaths during salvage. The main causes of death were sepsis (58%) and disease progression (21%). Consolidation therapy was delivered to 11 of the 14 responders. Six patients received this phase of treatment after one course of chemotherapy (induction), and five received it after two courses of chemotherapy (induction + salvage). Three patients did not receive the consolidation course because of early relapse (one case) and hematological toxicity (two cases). Ten patients received the maintenance course, which was ongoing in two cases. Seven patients stopped the maintenance treatment because of relapse and one because of respiratory insufficiency. No prognostic factor of CR achievement, including age, karyotype, bone marrow blastosis, AML status, FAB classification, and white blood cell count could be found (data not shown).
Median overall survival rate was 4 months for the whole population (Figure 1) , and median DFS was 9.6 months in the Figure 1 Overall survival for all the patients (n = 51).
Figure 2
Disease-free survival for CR + PR patients (n = 14).
14 responding patients ( Figure 2 ). Five patients were still alive, after 15 to 21 months of follow-up (median 16 months). Among these five patients, two were still in CR and three had relapsed.
Pharmacokinetic results (Table 6) Residual plasma levels of idarubicinol were detected on day 8 after intake, ranging from 0.5 ng/ml to 1.3 ng/ml (median 1 ng/ml). Plasma levels of idarubicinol were not higher after salvage than after induction. There was no drug accumulation in the patients tested, although we observed a moderate increase in plasma idarubicinol levels on day 15 of treatment. This was observed during induction, and also for patients who received both induction and salvage courses. Results were homogeneous and reproducible.
Discussion
The safety and efficacy of oral ZVD has already been assessed, either alone or in combination with other drugs. At least two trials of oral ZVD monotherapy in the treatment of AML in elderly patients have been reported. In the study by Lowenthal et al 10 nine previously untreated patients with a median age of 75 years received oral ZVD at a dose of 20-25 mg/m 2 /day 3 days running. An objective response was noted in five patients, with two CR and three PR. The other study reported a series of 20 untreated AML patients with a median age of 72 years who received oral ZVD at a dose of 30 mg/m 2 /day 3 days running. Eight patients (40%) entered CR. 11 These two reports clearly demonstrate that oral ZVD is active in elderly Table 6 Plasma levels of idarubicinol The reported data correspond to the median, with ranges in parentheses.
Results are expressed in ng/ml. NA, not assessable.
AML patients. However, when ZVD is delivered for 3 consecutive days the pattern of myelosuppression is comparable to that observed with the intravenous route, both for hematological and extrahematological toxicities. Oral ZVD has also been used in combination with antineoplastic drugs in the management of elderly AML patients. The combination of oral ZVD (20 mg/m 2 /day for 3 days) with subcutaneous LD Ara-C (10 mg/m 2 every 12 h for 10 days) has been tested in 32 untreated AML patients with a median age of 76 years. Fifty patients responded, with 13 CR (40%) and two PR. 13 These data compare favorably to those reported by Jackson et al, 15 who used an all-oral chemotherapy regimen consisting of ZVD 30 mg/m 2 and etoposide 80 mg/m 2 for 3 consecutive days. The regimen was assessed in 25 patients with a median age of 69 years. Eleven patients responded, with nine CR (36%) and two PR. Finally, results of all these trials prove the safety and efficacy of idarubicin-based oral chemotherapy in elderly patients with AML, with results comparable to those of conventional chemotherapy. However, the toxicity remains high, and patients had to be entirely managed in hospital.
The aim of our study was to evaluate the safety and efficacy of weekly treatment with oral ZVD monotherapy in ambulatory elderly AML patients. This regimen was based on the long terminal half-life of idarubicinol. Patients who entered this trial were an unselected cohort of poor risk patients mainly because they had a contraindication to intensive intravenous chemotherapy. Such an argument certainly constitutes an adverse prognostic factor, as supportive care or low-dose chemotherapy (such as low-dose Ara-C) in those patients yields only a short survival. Furthermore, the median age of our population was higher than in most published series of elderly AML, with 88% of patients over 70 years and 57% over 75 years of age. Despite these poor risk features, 12 patients (25%) achieved a CR, seven of them after receiving the salvage course. These responding patients showed the same characteristics as the whole population. None of the prognostic factors we tested significantly influenced the probability of CR achievement, but this may have been due to the small number of patients. Of these 12 CR patients, three (25%) never required hospitalization and were totally ambulatory. Nine of them stayed or were readmitted in hospital, four during induction (median 20.5 days), and five during induction plus salvage (median 42 days). Thus, these responding patients were less hospitalized than patients intensively treated with intravenous regimens. The main toxicity of this regimen was hematological, and mainly occurred during the salvage course. Indeed, 87% of all the patients had to be hospitalized during this phase of treatment, for a median of 17.5 days. On the other hand, nearly 40% of patients received the induction course while ambulatory; when required, hospitalization was shorter (median 14.5 days). Blood product requirements remained moderate in this elderly population. Transfusions were substantially higher during the salvage phase than during the induction phase. Overall tolerance of the consolidation course was satisfactory, fewer than 40% of patients requiring hospitalization. Febrile neutropenia and documented infections were frequent and often severe, requiring parenteral antibiotics. The profound immunosuppression and ensuing infections resulted both from the underlying disease and the treatment. Extrahematological toxicity was mild in all three phases of treatment. There were three toxic deaths (6%), two from hemorrhage and one from pulmonary embolism.
Weekly oral idarubicin treatment is well tolerated in poorrisk elderly patients with AML. The toxicity remains acceptable, and the outpatient schedule of this regimen could be observed for approximately one-third of patients. The CR rate is satisfactory, but in our experience, more than half of the patients required two courses to achieve CR. The apparent efficacy of the salvage course relative to the induction course may be explained in two ways. First, bioavailability may have been too low during the induction course, and substantially increased by the doubling of the dose in the salvage phase. Unfortunately, our pharmacokinetic data on the salvage course only concerned seven patients, of whom three were not evaluable for response to treatment. Second, patients who received the salvage sequence were exposed to the drug for a longer total period of time. These hypotheses highlight the variability of absorption of oral drugs from the gut. However, several crossover studies have determined the bioavailability of idarubicin. Some authors have compared the two routes of administration (oral and intravenous) in similar patients, and these studies gave similar estimates of the bioavailability of idarubicin. 20 In an effort to find the optimal oral idarubicin schedule in this elderly AML population, we are currently testing an induction regimen with a dose at 40 mg/m 2 /week during 4 consecutive weeks.
Results of this trial show that this new weekly ambulatory schedule of oral ZVD chemotherapy is feasible and effective in poor risk elderly patients with AML. This regimen may be helpful for patients unable to tolerate intensive intravenous regimens, and is a real alternative to palliative treatments. While CR has been the main objective of consecutive trials for many years, quality of life and reduced hospitalization also need to be assessed.
